Physician profile
Lisa Eng
NPI 1952373912
$218,767.84
in general payments reported to CMS, 2019-2025
44 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $24K · 2021: $24K · 2022: $13K · 2023: $39K · 2024: $19K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Travel and Lodging: $15K · Food and Beverage: $7,596 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,042.50 |
| Travel and Lodging | $14,829.24 |
| Food and Beverage | $7,596.29 |
| Education | $403.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112,683.58 | 2019-2023 | |
| Astellas Pharma US INC | $96,504.69 | 2021-2025 | Veozah |
| Myovant Sciences INC. | $2,445.02 | 2021-2022 | |
| Glaxosmithkline, LLC. | $1,130.57 | 2022-2025 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $536.41 | 2020-2023 | Injectafer |
| Novo Nordisk INC | $516.28 | 2019-2025 | Wegovy, Ozempic |
| Mayne Pharma Commercial LLC | $376.49 | 2023-2025 | |
| Avion Pharmaceuticals | $361.13 | 2019-2022 | |
| Pfizer INC. | $325.89 | 2021-2025 | |
| Lupin INC. | $311.78 | 2019-2020 | |
| Agile Therapeutics, INC. | $275.05 | 2021 | |
| Hologic Sales and Service, LLC | $251.33 | 2021-2024 | Omni Hysteroscope, Acessa Provu System, Novasure |
| Exeltis, USA INC. | $244.79 | 2021-2025 | Slynd, Twirla |
| Shield Therapeutics INC | $193.68 | 2023-2025 | Accrufer |
| Evofem Biosciences, INC. | $192.48 | 2021-2022 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.